Karyopharm Therapeutics Inc (KPTI) EVP Sells $19,500.00 in Stock

Karyopharm Therapeutics Inc (NASDAQ:KPTI) EVP Christopher Brett Primiano sold 1,500 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $13.00, for a total value of $19,500.00. Following the completion of the transaction, the executive vice president now directly owns 9,881 shares of the company’s stock, valued at $128,453. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Christopher Brett Primiano also recently made the following trade(s):

  • On Tuesday, December 12th, Christopher Brett Primiano sold 27,042 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $10.28, for a total value of $277,991.76.

Shares of Karyopharm Therapeutics Inc (NASDAQ KPTI) opened at $13.06 on Friday. The stock has a market capitalization of $677.61, a price-to-earnings ratio of -4.93 and a beta of 4.11. Karyopharm Therapeutics Inc has a 52 week low of $7.48 and a 52 week high of $14.63.

A number of research firms have recently commented on KPTI. ValuEngine raised Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday. BidaskClub raised Karyopharm Therapeutics from a “hold” rating to a “buy” rating in a report on Friday. Jefferies Group reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a report on Friday, October 13th. Robert W. Baird reaffirmed a “buy” rating on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. Finally, Cantor Fitzgerald set a $18.00 price target on Karyopharm Therapeutics and gave the stock a “buy” rating in a report on Tuesday, December 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $17.33.

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Karyopharm Therapeutics by 31.1% during the second quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock valued at $14,675,000 after buying an additional 384,658 shares during the period. State Street Corp boosted its stake in Karyopharm Therapeutics by 10.1% during the second quarter. State Street Corp now owns 511,920 shares of the company’s stock valued at $4,631,000 after buying an additional 47,127 shares during the period. Candriam Luxembourg S.C.A. boosted its stake in Karyopharm Therapeutics by 16.4% during the third quarter. Candriam Luxembourg S.C.A. now owns 510,000 shares of the company’s stock valued at $5,600,000 after buying an additional 72,000 shares during the period. Teachers Advisors LLC boosted its stake in Karyopharm Therapeutics by 2.6% during the second quarter. Teachers Advisors LLC now owns 431,350 shares of the company’s stock valued at $3,904,000 after buying an additional 10,787 shares during the period. Finally, Northern Trust Corp boosted its stake in Karyopharm Therapeutics by 36.5% during the second quarter. Northern Trust Corp now owns 405,374 shares of the company’s stock valued at $3,668,000 after buying an additional 108,369 shares during the period. 58.02% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Karyopharm Therapeutics Inc (KPTI) EVP Sells $19,500.00 in Stock” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://sportsperspectives.com/2018/02/10/karyopharm-therapeutics-inc-kpti-evp-sells-19500-00-in-stock.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply